Therapy News and Research

RSS

Breakthrough in understanding mechanisms behind hereditary alpha-1-antitrypsin deficiency

Researchers from the Royal College of Surgeons in Ireland (RCSI) and Beaumont Hospital have made a breakthrough in understanding the mechanisms behind the most severe form of hereditary emphysema and how protein treatments can improve the condition. The findings of this study may also lead to new treatments for patients with smoker's emphysema.

24 Jan 2011

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

Northwest Biotherapeutics announced today that the Company is resuming enrollment of additional new patients into its ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical trial of DCVax for Glioblastoma multiforme brain cancer.

24 Jan 2011

Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis

Raptor Pharmaceutical Corp., today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

24 Jan 2011

FDA approves Clinical Data's Viibryd for major depressive disorder

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD).

24 Jan 2011

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

Immune Network, a company in the business of development and commercialization of immune therapies, announced today that its newly acquired business, Immunitor, has published interim data from the ongoing Phase IIb imm01 clinical trial of V5 in tuberculosis conducted at its second site in Ukraine.

24 Jan 2011

Radiation Therapy Services to issue $50M of 9-7/8% Senior Subordinated Notes due 2017

Radiation Therapy Services Holdings, Inc.announced today that its wholly owned subsidiary, Radiation Therapy Services, Inc., has agreed to issue an aggregate principal amount of $50 million of 9-7/8% Senior Subordinated Notes due 2017.

24 Jan 2011

Boehringer Ingelheim's Prazaxa receives Japanese approval for stroke prevention in AF patients

The Ministry of Health, Labour and Welfare in Japan today approved dabigatran etexilate, Boehringer Ingelheim's novel, oral direct thrombin inhibitor under the brand name Prazaxa for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation marking the first approval of a novel oral anticoagulant in the Asia-Pacific region and specifically Japan in nearly 50 years.

24 Jan 2011

Tamoxifen may reduce individual's risk of death from lung cancer: New study

A new study has found that tamoxifen, an anti-estrogen breast cancer medication, may reduce an individual's risk of death from lung cancer.

24 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

First U.S. implant of RespiCardia System for treatment of sleep apnea

Cardiac Concepts, announced today the first U.S. clinical implant of the RespiCardia System at The Ohio State University Medical Center, Columbus, Ohio.

21 Jan 2011

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that repeated therapy cycles of its proprietary antibody, clivatuzumab tetraxetan, labeled with yttrium-90 plus low-dose gemcitabine, extended median overall survival.

21 Jan 2011

Everist Genomics reports positive results from OncoDefender-CRC assay external validation study

Everist Genomics, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, today announced the positive results of the first external validation study of its OncoDefender-CRC colorectal cancer recurrence test. The study is being conducted by Mayo Validation Support Services, and is being coordinated with investigators and resources from all three Mayo Clinic sites.

21 Jan 2011

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

NewLink Genetics Corporation today announced that additional data from its Phase 2 clinical trial of the company's investigational HyperAcute® Pancreas cancer immunotherapy will be presented during a poster session at the American Society of Clinical Oncology 2011 Gastrointestinal Cancers Symposium in San Francisco, California.

21 Jan 2011

How genetic abnormalities transform normal cells into leukemic cells

Cancer scientists led by Dr. John Dick at the Ontario Cancer Institute (OCI) and collaborators at St Jude Children's Research Hospital (Memphis) have found that defective genes and the individual leukemia cells that carry them are organized in a more complex way than previously thought.

21 Jan 2011

AHF proposes funding solutions to current ADAP crisis

In anticipation of an additional round of cuts to the AIDS Drug Assistance Program (ADAP) to be implemented in the next few months, AIDS Healthcare Foundation (AHF) today proposed three possible funding solutions to the current ADAP crisis—which has left more than 5,000 people on waiting lists to receive lifesaving medications and thousands more scheduled to be disenrolled from the program altogether. Currently,

21 Jan 2011

EMA CHMP issues negative opinion against Biogen Idec's FAMPYRA for multiple sclerosis

Biogen Idec announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union. Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.

21 Jan 2011

BOKA Powell releases new images of Methodist Hospital for Surgery in Texas

BOKA Powell released new images today of the completed Methodist Hospital for Surgery in Addison, Texas, a dedicated surgical hospital which opened last month.

21 Jan 2011

Precision highlights role of ChemoFx test, multi-gene predictors for breast cancer

In a new study in which Precision Therapeutics' Multi-Gene Predictors were independently validated by investigators at US Oncology and MD Anderson, Precision highlights the potential role of the ChemoFx® in vitro chemosensitivity test and multi-gene predictors in determining a patient's likelihood of response to multi-drug chemotherapy regimens in breast cancer.

21 Jan 2011

Pervasis to present PVS-10200 interim data from Phase 1/2 PAD clinical study at IC3D

Pervasis Therapeutics, Inc. today announced it will present interim data from the company's Phase 1/2 clinical study of PVS-10200, an investigational cell-based therapy under development to prevent restenosis in patients with peripheral arterial disease (PAD) who undergo an angioplasty and stent procedure in the superficial femoral artery.

21 Jan 2011

EHSI's NASA bioreactor will help reduce pain and trauma caused by harvesting of adult stem cells

Emerging Healthcare Solutions, Inc. expects that the company's NASA-developed bioreactor will help reduce patients' pain and trauma caused by the harvesting of adult stem cells for therapeutic and research purposes, said EHSI President and CEO Cindy Morrissey.

21 Jan 2011

Therapy News and Research

Breakthrough in understanding mechanisms behind hereditary alpha-1-antitrypsin deficiency

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis

FDA approves Clinical Data's Viibryd for major depressive disorder

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

Radiation Therapy Services to issue $50M of 9-7/8% Senior Subordinated Notes due 2017

Boehringer Ingelheim's Prazaxa receives Japanese approval for stroke prevention in AF patients

Tamoxifen may reduce individual's risk of death from lung cancer: New study

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

First U.S. implant of RespiCardia System for treatment of sleep apnea

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Everist Genomics reports positive results from OncoDefender-CRC assay external validation study

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

How genetic abnormalities transform normal cells into leukemic cells

AHF proposes funding solutions to current ADAP crisis

EMA CHMP issues negative opinion against Biogen Idec's FAMPYRA for multiple sclerosis

BOKA Powell releases new images of Methodist Hospital for Surgery in Texas

Precision highlights role of ChemoFx test, multi-gene predictors for breast cancer

Pervasis to present PVS-10200 interim data from Phase 1/2 PAD clinical study at IC3D

EHSI's NASA bioreactor will help reduce pain and trauma caused by harvesting of adult stem cells

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News